CD36 and hyperlipidemia: As noted previously, CD36 signaling contributes to platelet hyperactivity under conditions of hyperlipidemia and chronic inflammation which not only promotes thrombosis, but also facilitates platelet–monocyte interactions (Lee et al., 2019; Podrez et al., 2007; Yang et al., 2017).